topic

1345 mTFF2-MSA (mTNX-1700) suppresses tumor growth and increases survival in anti-PD-1 treated CT26.wt subcutaneous and CT26-Luciferase orthotopic syngeneic colorectal cancer models by targeting MDSCs
Bruce L Daugherty, Rebecca J Boohaker, Rebecca Johnstone, Karr Stinson, Grace Zhao, Mingfa Zang, Jin Qian, Timothy C Wang, Seth Lederman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1499; DOI: 10.1136/jitc-2023-SITC2023.1345
1346 mTFF2-MSA (mTNX-1700) suppresses tumor growth in an Anti-PD-1 treated Pan02 syngeneic pancreatic cancer model by targeting MDSCs in C57BL/6 Mice
Bruce L Daugherty, Grace Zhao, Mingfa Zang, Jin Qian, Timothy C Wang, Seth Lederman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1500; DOI: 10.1136/jitc-2023-SITC2023.1346
1347 Lactic acid uptake through MCT11 enforces dysfunction in terminally exhausted T cells
Greg Delgoffe, Ronal Peralta

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1501; DOI: 10.1136/jitc-2023-SITC2023.1347
1348 Development of enLIGHTEN™ Alpha-201 herpes simplex viral vectors encoding payloads targeting the tumor microenvironment
Anne R Diers, Qiuchen Guo, John D Christie, David Krisky, Karen Bouch, Paul P Tak, Francesca Barone

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1502; DOI: 10.1136/jitc-2023-SITC2023.1348
1349 Redirecting immune memory for cancer treatment using virus-inspired drug conjugates
Cayce Dorrier, Felagot Abebe, Olivia Pak, Emily De-Bodene, Joshua Wang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1503; DOI: 10.1136/jitc-2023-SITC2023.1349
1350 Neo-open reading frame peptides as a source of highly immunogenic neoantigens for mRNA therapeutic cancer vaccines
Katka Franke, Ronja Isabelle Mülfarth, Michael Martin, Salvador Aguilar-Rosas, Mark Pieterse, Jamie Langelaar, Wim van Esch, Renee van Schreurs, Hugo Olsman, Lisa van der Made, Bob Löwenberg, Ronald Plasterk, Janna Krüger, Regina Heidenreich, Wigard Kloosterman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1504; DOI: 10.1136/jitc-2023-SITC2023.1350
1351 Identifying IL-27 dependent biomarkers in lymphocytes, NK cells, and myeloid cells in peripheral blood and the tumor microenvironment
Karin Golan, Ricard Masia, Yue Ren, Yu Yang, Benjamin H Lee, Vito J Palombella, Jonathan A Hill

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1505; DOI: 10.1136/jitc-2023-SITC2023.1351
1352 An MHC class II targeted immunotherapy for CD33-positive pediatric acute myeloid leukemia
Lena Golick, Reeder Robinson, Lety Reyes, Nadia St Thomas, Nathan Dolloff

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1506; DOI: 10.1136/jitc-2023-SITC2023.1352
1353 An Fc-optimized B7-H3-targeting antibody for treatment of ovarian cancer
Ilona Hagelstein, Kevin Wang, Gundram Jung, Helmut R Salih, Martina S Lutz

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1507; DOI: 10.1136/jitc-2023-SITC2023.1353
1354 Anti-CCR8 antibody CHS-114 (SRF114) depletes tumor-infiltrating regulatory T cells in dissociated tumors from patients with head and neck squamous cell carcinoma
Robert R Haines, Marisella Panduro, Yu Yang, Yue Ren, Vito J Palombella, Jonathan A Hill, Ricard Masia, James F Mohan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1508; DOI: 10.1136/jitc-2023-SITC2023.1354

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages